Reporting for the family-office world.

Novel scientific insights to unlock the full potential of B cell therapeutics Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020 Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965 Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers Financing underway to fund AT-1965 clinical initiation and development What You Will Learn From This Webinar The importance of B Cells role in cancer immunotherapy Why AT-1965 is Poised to Lead the Next Frontier in Cancer Immunotherapy How our Phase 1 Study Design Provides a Strong Opportunity to Detect Clinical Activity in Cancer Patients How Reimagining Immunotherapy Will Move B Cell Treatments Beyond the Limits of History

Why Choice Housing Investments? The most recent completed quarter, gross annualized Cash on Cash returns were at 12.5% and the Preferred Return was delivered to all investors We continue to see opportunities for investment, yet are stable enough to be selective and not chase deals that have marginal returns Despite the current crisis, multifamily real estate has been a safe harbor. For the past two months, despite COVID and the related crisis, collections and occupancy have remained strong, especially versus other real estate sectors.

BACKGROUND ON COMPANY EPS is a privately held, technology driven company that is focused on developing new power solutions through the manufacturing of highly efficient, re-engineered, small sized turbine engines. Two separate models of these turbines will generate PRIMARY POWER (not just back-up power) for use in the residential, commercial, industrial, and retail sectors. One turbine will be powered by natural gas or any other liquid or gaseous fuel. The other engine will run on any form of solid waste biomass, including animal waste, grass, sugar cane waste, wood chips, wood pellets or algae. These uniquely designed engines are built to achieve superior efficiency that results in significant cost savings and substantial emission reductions.  These turbines are powerful enough to run anything from a village in Africa to a shopping mall, hospital, or educational facility in North America. These engines are portable, light weight and designed to fit on the back of a flat-bed truck or inside a standard shipping container. EPS has been granted exclusive access to the patents and other intellectual property on the enabling technology for their turbines through a long-term royalty-free license arrangement, with their manufacturing partner, Brayton Energy. Several prospective customers have signed Letters of Intent with EPS and are eager to purchase both models.  WHAT YOU WILL LEARN FROM THIS WEBINAR A live briefing from EPS Holdings representatives including Michael Daly, President and CEO on how EPS will provide an alternative cost efficient and “greener” solution to the way some people and end-users view power generation in the future. How the two EPS turbines can be used for multiple purposes in so many different sectors. The Company has raised U.S $6 million to date and is now seeking an additional U.S. $18 million to complete development and commence commercialization.

BACKGROUND ON COMPANY EPS is a privately held, technology driven company that is focused on developing new power solutions through the manufacturing of highly efficient, re-engineered, small sized turbine engines. Two separate models of these turbines will generate PRIMARY POWER (not just back-up power) for use in the residential, commercial, industrial, and retail sectors. One turbine will be powered by natural gas or any other liquid or gaseous fuel. The other engine will run on any form of solid waste biomass, including animal waste, grass, sugar cane waste, wood chips, wood pellets or algae. These uniquely designed engines are built to achieve superior efficiency that results in significant cost savings and substantial emission reductions.  These turbines are powerful enough to run anything from a village in Africa to a shopping mall, hospital, or educational facility in North America. These engines are portable, light weight and designed to fit on the back of a flat-bed truck or inside a standard shipping container. EPS has been granted exclusive access to the patents and other intellectual property on the enabling technology for their turbines through a long-term royalty-free license arrangement, with their manufacturing partner, Brayton Energy. Several prospective customers have signed Letters of Intent with EPS and are eager to purchase both models.  WHAT YOU WILL LEARN FROM THIS WEBINAR A live briefing from EPS Holdings representatives including Michael Daly, President and CEO on how EPS will provide an alternative cost efficient and “greener” solution to the way some people and end-users view power generation in the future. How the two EPS turbines can be used for multiple purposes in so many different sectors. The Company has raised U.S $6 million to date and is now seeking an additional U.S. $18 million to complete development and commence commercialization.

Background on Company The aerospace market is being disrupted by electrification, creating opportunities for new types of aircraft, improved economics, and lower emissions. Erik Lindbergh and a team of experienced technology and business leaders founded VerdeGo Aero to enable the next generation of clean, quiet, flight. VerdeGo Aero’s electric powertrains deliver significant competitive advantages for aircraft manufacturers focused on high performance and low operating costs. Customers in multiple aerospace market segments are leveraging VerdeGo Aero’s technologies in their next-generation aircraft designs. VerdeGo Aero is backed by strategic industry investors with more than 100 years of aviation experience, certification expertise, and supply chain capability. What You Will Learn From This Webinar The dramatic impact that CO2 reduction, noise restrictions, and COVID19 are having on the aerospace market; and how this is creating disruptive opportunities. How to differentiate between the reality and hype as more than 200 companies (VerdeGo’s customers) compete to design next generation electric aircraft. Competitive advantages that enable VerdeGo to efficiently and effectively create a $1B+ opportunity with significant upside potential for its investors.

BACKGROUND ON COMPANY Revolutionary cell therapy targeting a cure for both Type 1 and Type 2 diabetes Successful demonstration of curative properties in animal models, with a human clinical trial targeted for 2021 Utilization of ethically derived human induced pluripotent stem cells (iPSC, non-embryonic), which have the potential for significant scaleup to reach greater patient populations while avoiding ethical concerns RMS has been highly successful in obtaining significant non-dilutive capital from sources such as the NIH in order to supplement existing family office investors including Ratan Tata RMS’ patented stem cell technology is built on over 20 years of research and unique scientific expertise COVID-19 has demonstrated that diabetics are at significant risk for serious complications and death with the coronavirus, highlighting that diabetes puts significant parts of the population at risk WHAT YOU WILL LEARN FROM THIS WEBINAR Diabetes affects an estimated 463 million people worldwide and will rise to 700 million by 2040 without intervention, thus illustrating the urgent need for a therapeutic solution from RMS Diabetes and its complications are costing the world healthcare system an estimated $825 billion annually Learn how RMS’ technology can significantly reduce the great financial burden globally Every 6 seconds a person dies from diabetes and continues to be one of the world’s fastest growing diseases RMS’ therapeutic grade cells are directly analogous to the successful cadaveric islets procedure (insulin independence), but without the supply limitations, variability, high cost and inconsistencies of cadaver islets Investments in companies that treat/monitor diabetes have produced extraordinary results…imagine the potential investment returns of a company that can cure diabetes AgVest Advisors was started in 2018 by Chris Brawner to help institutions and individuals invest directly in US farmland. Chris has successfully invested ~$30M per year for current investors. Farmland is predominately a private market – Over 60% of AgVest investments are made through private deals using vast network of farmers and source points. AgVest Advisors provides full-service turnkey sourcing and on-going management services for direct farmland investments. Chris will work with investors to create thesis and source farmland deals with his extensive network. He negotiates on behalf of the buyer with seller, provides diligence post contract and manages assets post purchase.